Erasca to Present at the Jefferies Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York.
Management will join a fireside chat on June 3, 2026 at 3:10 p.m. ET, with a live and archived webcast on Erasca.com/events.
Details
News Market Reaction – ERAS
On May 27, the day this news came out, ERAS closed 8.43% above the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Fireside chat time
- 3:10 pm Eastern Time
- Jefferies Global Healthcare Conference on June 3, 2026
- Replay availability
- 30 days
- Archived webcast access period at Erasca.com/events
Historical Context
-
Q1 2026 results with widened net loss and RAS franchise investment.
-
Merck collaboration to evaluate ERAS-0015 with KEYTRUDA in solid tumors.
-
Bank of America health care conference fireside chat and investor meetings.
-
Positive preliminary Phase 1 dose-escalation data for ERAS-0015 in KRAS tumors.
-
Conference call and webcast to discuss preliminary ERAS-0015 Phase 1 data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ras/mapk pathway medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.